Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach?

Lung Cancer Manag. 2020 Feb 12;9(1):LMT22. doi: 10.2217/lmt-2019-0018.
No abstract available

Keywords: CheckMate; IMpower; KEYNOTE; POSEIDON; chemo-immunotherapy; first-line; immune checkpoint Inhibitors.

Publication types

  • Editorial